Volume 11, Number 3—March 2005
Dispatch
Inquilinus limosus in Patients with Cystic Fibrosis, Germany
Nele Wellinghausen*
, Andreas Essig*, and Olaf Sommerburg*
, Andreas Essig*, and Olaf Sommerburg*Table
Antimicrobial susceptibility of Inquilinus limosus strains
| Antimicrobial agent | MIC (µg/mL) | ||||
|---|---|---|---|---|---|
| Isolate A-1 | Isolate A-2 | Isolate A-3 | Isolate B | LMG 20952T | |
| Trimethoprim/sulfamethoxazole | >32 | >32 | >32 | >32 | >32 |
| Amikacin | 8 | 32 | 32 | >256 | >256 |
| Gentamicin | 8 | 16 | 12 | >256 | 12 |
| Tobramycin | >256 | >256 | >256 | >256 | >256 |
| Ampicillin | >256 | >256 | >256 | >256 | >256 |
| Piperacillin/tazobactam | >256 | >256 | >256 | >256 | >256 |
| Cefotaxime | >32 | >32 | >32 | >32 | >32 |
| Ceftazidime | 4 | 4 | 4 | 0.5 | 32 |
| Imipenem | 0.012 | 0.012 | 0.016 | 0.006 | 0.016 |
| Ciprofloxacin | 0.032 | 0.032 | 0.032 | 0.500 | 0.064 |
| Colistin* | Resistant | Resistant | Resistant | Resistant | Resistant |
*Susceptibility testing done by disk diffusion (see text); no zone of inhibition was seen.
